BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rezvilutamide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rezvilutamide\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05406999-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT05406999)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Neoadjuvant 
 Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Canc
 er\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05406999
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444983-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:Rezvilutamide: Phase na readout est. (NCT07444983)
DESCRIPTION:Rezvilutamide\, phase na\, Prostate Cancer.\nStudy: Rezvilutami
 de for High-Risk Prostate Cancer After Surgery\nEstimated primary completi
 on: 11 February 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /rezvilutamide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07444983
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05753566-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT05753566)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Rezvilutamid
 e in Patients With Biochemical Recurrence After Radical Prostatectomy for 
 Prostate Cancer\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05753566
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241416-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezvilutamide: Phase 3 readout est. (NCT07241416)
DESCRIPTION:Rezvilutamide\, phase 3\, Prostate Cancer.\nStudy: A Phase III 
 Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensit
 ive Prostate Cancer\nEstimated primary completion: March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07241416
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711314-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT07711314)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Adjuvant Rez
 vilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostat
 ectomy\nEstimated primary completion: May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07711314
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112209-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Rezvilutamide: Phase na readout est. (NCT07112209)
DESCRIPTION:Rezvilutamide\, phase na\, Prostate Cancer.\nStudy: Clinical St
 udy of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment
  of Abiraterone-Resistant Prostate Cancer\nEstimated primary completion: 1
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezvilut
 amide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07112209
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rezvilutamide: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:Rezvilutamide\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical
  Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Canc
 er\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305832-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT06305832)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: Salvage Radi
 otherapy Combined With Androgen Deprivation Therapy (ADT) With or Without 
 Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Pro
 statectomy for Prostate Cancer\nEstimated primary completion: March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06305832
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795177-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT07795177)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: A Prospectiv
 e Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combin
 ed With Second-generation Novel Hormonal Agents in Metastatic Hormone-sens
 itive Prostate Cancer.\nEstimated primary completion: 30 April 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07795177
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230106-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT07230106)
DESCRIPTION:Rezvilutamide\, phase 2\, Prostate Cancer.\nStudy: A Study of S
 HR3680\, HS-20093 and SHR2554 in Subjects With Prostate Cancer\nEstimated 
 primary completion: December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rezvilutamide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07230106
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348264-11066@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Rezvilutamide: Phase 2 readout est. (NCT06348264)
DESCRIPTION:Rezvilutamide\, phase 2.\nStudy: Adjuvant Rezvilutamide in Comb
 ination With Androgen Deprivation Therapy in Androgen Receptor-positive\, 
 High-risk Salivary Duct Carcinoma\nEstimated primary completion: 30 March 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06348
 264
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
